Open AccessShiga‐like toxin I exerts specific and potent anti‐tumour efficacy against gastric cancer cell proliferation when driven by tumour‐preferential Frizzled‐7 promoter
Author(s) -
Xu Hongpan,
Peng Lijun,
Shen Mengjiao,
Xia Yanyan,
Li Zhiyang,
He gyue
Publication year - 2019
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12607
Subject(s) - cancer , cancer research , cancer cell , cell growth , frizzled , biology , transfection , globotriaosylceramide , stomach cancer , cell culture , medicine , pathology , signal transduction , wnt signaling pathway , microbiology and biotechnology , biochemistry , genetics , fabry disease , disease
Objectives Tumour‐targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour‐targeting promoters with cytotoxins. Methods The expression of globotriaosylceramide (Gb3), which is a Shiga‐like toxin I (Stx1) receptor, was verified in gastric cancer compared with normal stomach tissues as assessed by flow cytometry and immunohistochemical analysis. We therefore constructed the recombinant pFZD7‐Stx1 plasmid vectors with tumour‐preferential Frizzled‐7 promoter and Stx1. pFZD7‐Stx1 was used to treat gastric cancer in vitro and in vivo. The gastric cancer cell proliferation and tumour growth were identified after the transfection with the pFZD7‐Stx1. Results Globotriaosylceramide was obviously increased in gastric cancer compared with normal stomach. The gastric cancer cell proliferation and tumour growth decreased significantly after the transfection with the pFZD7‐Stx1. Conclusion Frizzled‐7 promoter is preferentially active, and Gb3 is abundant in gastric cancer cells. Frizzled‐7 promoter and Stx1 may be used to determine a novel and relatively specific and potent gastric cancer therapeutic strategy.